‘Task Force: Start biennial mammograms at age 50
The U.S. Preventive Services Task Force is continuing to recommend routine mammograms every 2 years for women starting... More
Alzheimer’s drug improves cognitive function after RT for brain tumors
Adult brain tumor survivors taking donepezil, a drug approved for the treatment of Alzheimer’s disease, showed... More
Dr. Antoni Ribas
Pembrolizumab was superior to ipilimumab, the standard of care, as first-line therapy for advanced melanoma in the... More
Dr. Robert L. Coleman
CHICAGO – Adding the anti-angiogenic agent bevacizumab to chemotherapy improves outcomes in women with... More
VIDEO: TKIs merit broader use as NSCLC adjuvant
GENEVA – It’s time for oncologists to radically expand their use of adjuvant treatment with a tyrosine-kinase inhibitor... More
Dr. Anna Fagotti
CHICAGO – Delaying debulking until patients have had some chemotherapy is a safer strategy for women with advanced... More
Dr. Neil T. Phippen
CHICAGO– Quality of life at baseline and during treatment is an important prognostic factor in women with ovarian... More
doctor_arms_crossed
A coalition of physician, consumer, and other advocacy groups is asking politicians to stop trying to regulate the... More
Ms. Jennifer Horowitz
CHICAGO – A majority of health providers use some form of mobile technology to engage patients, but only half have... More
Health data breaches compromised 29 million patient records in 2010-2013
Some 29 million private patient health records were compromised between 2010 and the end of 2013 – mostly as a result... More
Erica Galvez
CHICAGO – The federal government’s Shared Nationwide Interoperability Roadmap lays out a grand vision for a single... More
Dr. Elizabeth Swisher
CHICAGO – Women whose ovarian cancers harbor a BRCA mutation or have a similar genomic signature are most likely to... More

News

M. ALEXANDER OTTO
The U.S. Preventive Services Task Force is continuing to recommend routine mammograms every 2 years for women starting at age 50, according to newly released draft screening recommendations for breast cancer. The draft recommendations, issued on Ap... More »
 

News

JENNIFER KELLY SHEPPHIRD
The immune checkpoint inhibitor nivolumab generated encouraging response rates and overall survival rates in heavily pretreated patients with non–small cell lung cancer, according to a report published online April 20 in the Journal of Clinical Onc... More »
 

Practice Economics

Reimbursement and Management

LUCAS FRANKI
Of all drugs to be released in 2015, the melanoma drug Opdivo (nivolumab) is expected to have the brightest future, according to a report from Thomson Reuters. With sales forecast to reach nearly $5.7 billion by 2019, Opdivo is at the head of a larg... More »
 

Policy & Practice Podcast

GREGORY TWACHTMAN
You can officially close the book on the Medicare Sustainable Growth Rate formula. Despite some close calls on amendment votes, the Senate ultimately passed with an overwhelming majority a clean bill repealing the formula. And with President Obama si... More »
 

Commentaries

Yes: Both patients and science can benefit from genomic analysis of tumors. Use of molecular profiling of gastrointestinal tumors is ready for prime time. My contention is that both patients and science can benefit from genomic analysis of tumors. ... More »
 

Commentaries

JEFFREY BENABIO, M.D.
Doctors have been conjecturing about how the new Apple Watch, with its spectacular fitness and wellness tracking features, will transform health care. The real rock star at Apple’s March 9 “Spring Forward” event, however, was the opening band, ... More »
 
PATRICE WENDLING
Pembrolizumab was superior to ipilimumab, the standard of care, as first-line therapy for advanced melanoma in the phase III KEYSTONE-006 trial. Pembrolizumab (Keytruda) hit all of its primary survival end points and nearly tripled response rates fr... More »
 
RENEE MATTHEWS
SAN ANTONIO – In a roundtable at the 2014 San Antonio Breast Cancer Symposium, Dr. Jame Abraham, Dr. Linda Bosserman, and Dr. Debra Patt discussed their top selections from the meeting’s presentations. Among the topics were the promising findin... More »